Heron Therapeutics (HRTX) Competitors $1.32 +0.02 (+1.54%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.03 (+2.65%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. TSHA, CRMD, URGN, RZLT, ABUS, PHAT, KOD, VALN, XNCR, and MNMDShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Taysha Gene Therapies (TSHA), CorMedix (CRMD), Urogen Pharma (URGN), Rezolute (RZLT), Arbutus Biopharma (ABUS), Phathom Pharmaceuticals (PHAT), Kodiak Sciences (KOD), Valneva (VALN), Xencor (XNCR), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors Taysha Gene Therapies CorMedix Urogen Pharma Rezolute Arbutus Biopharma Phathom Pharmaceuticals Kodiak Sciences Valneva Xencor Mind Medicine (MindMed) Taysha Gene Therapies (NASDAQ:TSHA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Is TSHA or HRTX more profitable? Heron Therapeutics has a net margin of -0.62% compared to Taysha Gene Therapies' net margin of -1,144.97%. Heron Therapeutics' return on equity of 0.00% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,144.97% -78.44% -44.82% Heron Therapeutics -0.62%N/A -0.40% Does the media favor TSHA or HRTX? In the previous week, Taysha Gene Therapies had 21 more articles in the media than Heron Therapeutics. MarketBeat recorded 21 mentions for Taysha Gene Therapies and 0 mentions for Heron Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.55 beat Heron Therapeutics' score of 0.00 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Overall Sentiment Taysha Gene Therapies Positive Heron Therapeutics Neutral Which has better valuation & earnings, TSHA or HRTX? Heron Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Heron Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M155.89-$89.30M-$0.34-14.00Heron Therapeutics$144.29M1.68-$13.58M-$0.02-66.00 Do analysts prefer TSHA or HRTX? Taysha Gene Therapies presently has a consensus price target of $9.00, suggesting a potential upside of 89.08%. Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 240.91%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80Heron Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals hold more shares of TSHA or HRTX? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, TSHA or HRTX? Taysha Gene Therapies has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. SummaryHeron Therapeutics beats Taysha Gene Therapies on 10 of the 16 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$238.31M$2.59B$6.05B$10.58BDividend YieldN/A56.45%5.68%4.69%P/E Ratio-66.0024.2277.3326.67Price / Sales1.68719.92598.94129.44Price / CashN/A172.4737.7361.25Price / Book-6.005.3412.556.55Net Income-$13.58M$32.92M$3.30B$277.26M7 Day Performance9.09%3.82%28,056.17%2.41%1 Month Performance-0.75%9.73%28,977.34%9.26%1 Year Performance-36.23%-2.15%35,796.37%32.66% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics3.5663 of 5 stars$1.32+1.5%$4.50+240.9%-37.8%$238.31M$144.29M-66.00300Positive NewsTSHATaysha Gene Therapies2.5506 of 5 stars$3.16-2.8%$8.29+162.2%+138.0%$886.58M$8.33M-9.29180Trending NewsAnalyst ForecastOptions VolumeGap UpCRMDCorMedix3.2151 of 5 stars$11.85+4.9%$18.00+51.9%+33.6%$882.06M$43.47M15.0730URGNUrogen Pharma3.9626 of 5 stars$19.14+4.4%$32.00+67.2%+35.7%$848.48M$90.40M-5.77200News CoveragePositive NewsAnalyst ForecastRZLTRezolute2.7821 of 5 stars$9.29-0.5%$14.50+56.1%+95.1%$848.18MN/A-9.5840Analyst RevisionABUSArbutus Biopharma1.2541 of 5 stars$4.46+1.1%$5.00+12.1%+15.1%$845.39M$6.17M-15.3890PHATPhathom Pharmaceuticals2.3312 of 5 stars$11.33-3.8%$17.50+54.5%-29.5%$835.72M$55.25M-2.40110KODKodiak Sciences2.7711 of 5 stars$15.81+0.1%$13.00-17.8%+412.6%$834.58MN/A-4.1690Gap UpVALNValneva2.6979 of 5 stars$10.95+12.8%$15.00+37.0%+100.9%$834.35M$183.52M-11.17700Gap UpXNCRXencor3.7135 of 5 stars$11.55-0.2%$22.25+92.6%-39.3%$825.21M$110.49M-4.81280Positive NewsMNMDMind Medicine (MindMed)2.4348 of 5 stars$12.04+12.8%$26.50+120.1%+120.2%$811.86MN/A-7.8740High Trading Volume Related Companies and Tools Related Companies Taysha Gene Therapies Competitors CorMedix Competitors Urogen Pharma Competitors Rezolute Competitors Arbutus Biopharma Competitors Phathom Pharmaceuticals Competitors Kodiak Sciences Competitors Valneva Competitors Xencor Competitors Mind Medicine (MindMed) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HRTX Stock Alerts